{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:59:21Z","timestamp":1791917961731,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40257-023-00840-1","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T14:02:11Z","timestamp":1705672931000},"page":"327-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9382-7671","authenticated-orcid":false,"given":"Wilson","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"10247","key":"840_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"6","key":"840_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393.","journal-title":"Allergy"},{"issue":"Suppl 1","key":"840_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000370220","volume":"66","author":"S Nutten","year":"2015","unstructured":"Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8\u201316.","journal-title":"Ann Nutr Metab"},{"issue":"6","key":"840_CR4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571\u201392.","journal-title":"Dermatology"},{"issue":"10","key":"840_CR5","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau K, Pandya AG, Ezzedine K, Jones H, Gao J, Lindley A, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan, and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"840_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"840_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.20596","volume":"186","author":"V Eleftheriadou","year":"2022","unstructured":"Eleftheriadou V, Atkar R, Batchelor J, McDonald B, Novakovic L, Patel JV, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18\u201329.","journal-title":"Br J Dermatol"},{"issue":"10244","key":"840_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110\u201320.","journal-title":"Lancet"},{"issue":"4","key":"840_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","volume":"77","author":"EL Simpson","year":"2017","unstructured":"Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623\u201333.","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"840_CR10","first-page":"343","volume":"3","author":"M Rashighi","year":"2015","unstructured":"Rashighi M, Harris JE. Interfering with the IFN-\u03b3\/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med. 2015;3(21):343.","journal-title":"Ann Transl Med."},{"issue":"3","key":"840_CR11","volume":"2","author":"L Bao","year":"2013","unstructured":"Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3): e24137.","journal-title":"JAKSTAT."},{"issue":"1","key":"840_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217\u201328.","journal-title":"Cell"},{"key":"840_CR13","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.","journal-title":"Front Immunol"},{"issue":"15","key":"840_CR14","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood"},{"issue":"4","key":"840_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield L, Leung DY, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372.","journal-title":"J Am Acad Dermatol"},{"key":"840_CR16","volume-title":"Full Prescribing Information","author":"Opzelura\u2122 (ruxolitinib cream)","year":"2023","unstructured":"Opzelura\u2122 (ruxolitinib cream). Full Prescribing Information. Wilmington: Incyte Corporation; 2023."},{"issue":"5","key":"840_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2023;88(5):1008\u201316.","journal-title":"J Am Acad Dermatol"},{"key":"840_CR18","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387:1445\u201355.","journal-title":"N Engl J Med"},{"key":"840_CR19","doi-asserted-by":"publisher","first-page":"204209862211250","DOI":"10.1177\/20420986221125006","volume":"13","author":"S Lucas","year":"2022","unstructured":"Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance: reporting requirements throughout a product\u2019s lifecycle. Ther Adv Drug Saf. 2022;13:20420986221125006.","journal-title":"Ther Adv Drug Saf."},{"key":"840_CR20","unstructured":"US FDA. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment: Guidance for Industry. 2005. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment. Accessed 12 Jun 2023."},{"key":"840_CR21","unstructured":"Delong C, Preuss CV. Black box warning. StatPearls. Treasure Island, FL: StatPearls Publishing; 2023."},{"key":"840_CR22","unstructured":"US FDA. Prescribing Information Resources: For Industry. 2023. https:\/\/www.fda.gov\/drugs\/fdas-labeling-resources-human-prescription-drugs\/prescribing-information-resources#:~:text=What%20is%20the%20Prescribing%20Information,the%20labeled%20conditions%20of%20use. Accessed 8 Jun 2023."},{"issue":"4","key":"840_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"840_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002236","volume":"8","author":"TW Kragstrup","year":"2022","unstructured":"Kragstrup TW, Glintborg B, Svensson AL, McMaster C, Robinson PC, Deleuran B, et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8(1): e002236.","journal-title":"RMD Open"},{"key":"840_CR25","unstructured":"US FDA. Postmarketing Adverse Event Reporting Compliance Program. https:\/\/www.fda.gov\/drugs\/surveillance\/postmarketing-adverse-event-reporting-compliance-program. Accessed 29 Sep 2023."},{"key":"840_CR26","unstructured":"US FDA. What Is a Serious Adverse Event? 2023. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event. Accessed 9 Jun 2023."},{"key":"840_CR27","unstructured":"European Medicines Agency. Inclusion\/exclusion criteria for the \"Important Medical Events\" list. European Medicines Agency. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/other\/inclusion-exclusion-criteria-important-medical-events-list-meddra_en.pdf. Accessed 29 Sep 2023."},{"issue":"3","key":"840_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/ph15030298","volume":"15","author":"AC Brabete","year":"2022","unstructured":"Brabete AC, Greaves L, Maximos M, Huber E, Li A, Le ML. A sex- and gender-based analysis of adverse drug reactions: a scoping review of pharmacovigilance databases. Pharmaceuticals (Basel). 2022;15(3):298.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"840_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","volume":"22","author":"X Gong","year":"2021","unstructured":"Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E, et al. Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies. Am J Clin Dermatol. 2021;22(4):555\u201366.","journal-title":"Am J Clin Dermatol"},{"key":"840_CR30","volume-title":"Summary of Product Characteristics","author":"Opzelura\u2122 (ruxolitinib cream)","year":"2023","unstructured":"Opzelura\u2122 (ruxolitinib cream). Summary of Product Characteristics. Amsterdam: Incyte Biosciences Distribution B.V.; 2023."},{"issue":"1","key":"840_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/11593280-000000000-00000","volume":"13","author":"AO Jensen","year":"2012","unstructured":"Jensen AO, Svaerke C, K\u00f6rmendin\u00e9 Farkas D, Olesen AB, Kragballe K, S\u00f8rensen HT. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977\u20132006). Am J Clin Dermatol. 2012;13(1):29\u201336.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"840_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5826\/dpc.0702a01","volume":"7","author":"Z Apalla","year":"2017","unstructured":"Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. Epidemiological trends in skin cancer. Dermatol Pract Concept. 2017;7(2):1\u20136.","journal-title":"Dermatol Pract Concept."},{"issue":"2","key":"840_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ehjacc\/zuab108","volume":"11","author":"A Prepoudis","year":"2022","unstructured":"Prepoudis A, Koechlin L, Nestelberger T, Boeddinghaus J, Lopez-Ayala P, Wussler D, et al. Incidence, clinical presentation, management, and outcome of acute pericarditis and myopericarditis. Eur Heart J Acute Cardiovasc Care. 2022;11(2):137\u201347.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"2","key":"840_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/13696998.2019.1669329","volume":"23","author":"D Weycker","year":"2020","unstructured":"Weycker D, Hanau A, Hatfield M, Wu H, Sharma A, Bensink ME, et al. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. J Med Econ. 2020;23(2):184\u201392.","journal-title":"J Med Econ"},{"key":"840_CR35","unstructured":"Institute of Medicine of the National Academies. Challenges for the FDA: The Future of Drug Safety. Workshop Summary. Washington, DC: Institute of Medicine Forum on Drug Discovery, Development, and Translation; 2007."},{"issue":"1","key":"840_CR36","first-page":"127","volume":"2","author":"D Kavitha","year":"2010","unstructured":"Kavitha D. Adverse drug reaction (ADR) monitoring and pharmacovigilance. J Pharm Res Health Care. 2010;2(1):127\u201334.","journal-title":"J Pharm Res Health Care."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00840-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00840-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00840-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:08:38Z","timestamp":1707955718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00840-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00840-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"18 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Incyte Corporation, Wilmington, DE, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Wilson Hu, Michele Thornton, and\u00a0Robert A. Livingston are employees and shareholders of Incyte.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts Of Interest\/Competing Interests"}},{"value":"No data generated or analyzed during the current study will be deposited.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability Of Data And Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors (1) made substantial contributions to the conception and design of the work; and the acquisition, analysis, and interpretation of data; (2) drafted the work and revised it critically for important intellectual content; (3) approved the version to be published; and (4) agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}